Available Until 2/8/2025
View Cart

COVID-19 Now and Beyond: Where Do We Go From Here?

ACPE Activity Number:   0204-0000-23-412-H01-P
Content Release Date: February 8, 2024
Expiration Date: February 8, 2025
Activity Type: Application-based   
CE Credits: 1.5 contact hours (0.15 CEUs)
Activity Fee: Free

Activity Overview

Although the COVID-19 Public Health Emergency (PHE) Declaration expired on May 11, 2023, COVID-19 continues to be top of mind in the healthcare community. Pharmacists have been integral in the fight against COVID-19. This educational activity will provide an update on the pharmacist’s role in current COVID-19 prevention and treatment strategies. Now that the PHE Declaration has expired, the potential implications of coverage and access to vaccines, therapies, and tests will be explained. Prevention and management strategies for COVID-19 in special patient populations will also be summarized. The activity will conclude with a review of new and emerging therapies for the prevention and treatment of COVID-19.

*Please note, this activity was presented live on December 5, 2023 as part of the ASHP 2023 Midyear Clinical Meeting & Exhibition. You can only claim credit once for this activity; live or home study

More in this Series:

Office Hours: Office Hours Roundtable: Enhancing Care for Special Patient Populations in the Shadow of the COVID-19 Pandemic

Engaging the Experts Podcasts: Coming April and June of 2024

 

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

This activity was planned to meet the educational needs of pharmacists who practice in hospitals and health systems.

After participating in this CPE activity, learners should be able to:

  • Describe the pharmacist’s role in COVID-19 prevention and treatment strategies.
  • Discuss barriers to equitable access to COVID-19 vaccines and therapeutics.
  • Assess prevention and management strategies for COVID-19 in special patient populations.
  • Evaluate new and emerging therapies for the prevention and treatment of COVID-19.

Katherine Yang, PharmD, MPH, FCSHP
Co-Vice Dean, Clinical Innovation and Entrepreneurship and Professor
UCSF School of Pharmacy
Infectious Diseases Clinical Pharmacist
UCSF Medical Center
San Francisco, California



Katherine Yang, PharmD, MPH, FCSHP is a Health Sciences Clinical Professor of Pharmacy at the UCSF School of Pharmacy and an infectious diseases clinical pharmacist at the UCSF Medical Center in San Francisco, California. Dr. Yang specializes in the pharmacokinetic and pharmacodynamic optimization of antibiotic dosing for the treatment of multi-drug resistant gram-negative infections. Since the start of the pandemic, Dr. Yang has been heavily involved in the management of COVID-19 therapeutics. 

 

Monica V. Mahoney, PharmD, BCPS, BCIDP, FCCP, FIDSA, FIDP
Clinical Pharmacy Specialist, Infectious Diseases
Beth Israel Deaconess Medical Center
Boston, Massachusetts



Monica Mahoney, PharmD, BCPS, BCIDP, FCCP is a clinical pharmacy specialist in the outpatient infectious diseases and outpatient parenteral antibiotic therapy clinics at Beth Israel Deaconess Medical Center. Dr. Mahoney received her PharmD degree from Massachusetts College of Pharmacy and Health Sciences in Boston, Massachusetts. She completed postgraduate year 1 residency and postgraduate year 2 infectious diseases residency at Tufts Medical Center in Boston, Massachusetts. She is an active member of many pharmacy and infectious diseases professional organizations, including ASHP, the Society of Infectious Diseases Pharmacists, and the Infectious Diseases Society of America.

 

Sarah Parsons, PharmD, BCPPS
Clinical Pharmacy Specialist Pediatric Infectious Diseases, Antimicrobial Stewardship Co Lead
The Children's Hospital of the King's Daughters
Norfolk, Virginia


Sarah Parsons, PharmD, BCPPS is a clinical pharmacy specialist in pediatric infectious diseases at the Children’s Hospital of the King’s Daughters focusing in antimicrobial stewardship and COVID-19 management in pediatric patients. Dr. Parsons received her Bachelor of Science focused in microbiology and immunology from Radford University followed by her Doctor of Pharmacy Degree from Virginia Commonwealth School of Pharmacy. She completed a postgraduate year 1 residency at HCA Health system in Richmond, Virginia.

Michael Ganio, PharmD, MS, BCPS, FASHP
Senior Director, Pharmacy Practice and Quality
ASHP
Bethesda, Maryland


Michael Ganio, PharmD, MS, BCPS, FASHP joined the staff at ASHP as Director of Pharmacy Practice and Quality in January of 2018. As a member of the Center on Medication Safety and Quality team, his responsibilities span the practice of pharmacy and include drug shortages, pharmaceutical quality, sterile and non-sterile drug compounding practices, hazardous drug handling, and the ASHP Standardize 4 Safety initiative. Dr. Ganio earned his Pharm.D. from the Rutgers University Ernest Mario School of Pharmacy and his Master’s degree in Health-System Pharmacy Administration from The Ohio State University College of Pharmacy. He completed a PGY1 Pharmacy Practice residency at The Ohio State University Wexner Medical Center. Dr. Ganio is a Board Certified Pharmacotherapy Specialist (BCPS) and is a Certified Professional in Healthcare Information and Management Systems (CPHIMS).

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company. 

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.

The following persons in control of this activity’s content have relevant financial relationships:

  •          Monica V. Mahoney: BD Bioscience – Consultant, Speaker’s bureau, GSK – Consultant , Cidara – Consultant, Pfizer – Consultant

All other persons in control of content do not have any relevant financial relationships with an ineligible company.

As defined by the Standards of Integrity and Independence in Accredited Continuing Education definition of ineligible company. All relevant financial relationships have been mitigated prior to the CE activity.

Activities can be completed in any order. Each activity consists of audio, video and an evaluation. Learners must review all content and complete an evaluation to receive continuing education credit for each activity.

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

Per ACPE requirements, CPE credit must be claimed within 60 days of being earned – no exceptions! To verify that you have completed the required steps and to ensure your credits have been reported to CPE Monitor, we encourage you to check your NABP eProfile account to validate your credits were transferred successfully before the ACPE 60-day deadline. After the 60 day deadline, ASHP will no longer be able to award credit for this activity.

Provided by ASHP
Supported by an educational grant from AstraZeneca